Shearman & Sterling is advising Boston Scientific Corporation on its acquisition of Endo International’s American Medical Systems (AMS) urology portfolio, which includes the men's health and prostate health businesses, in a transaction valued at $1.6 billion, with a potential additional payment of $50 million based on 2016 sales of the business. The company expects to close the transaction in the third quarter of 2015, subject to customary closing conditions.
Based in Minnetonka, Minn., the AMS Men's Health and Prostate Health businesses include approximately 800 employees worldwide, and generated 2014 sales of approximately $400 million and adjusted operating income of approximately $130 million, excluding amortization and certain allocated expenses.
Boston Scientific Corporation is a leading innovator of medical solutions that improve the health of patients around the world. The company’s products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health, and chronic pain conditions.